Ranger banner image

Effortless Deliverability. Exceptional Outcomes.

Ranger Drug-Coated Balloon

Ranger™️drug-coated balloon consistently delivers exceptional outcomes with effortless deliverability

Exceptional outcomes with effortless deliverability

The innovative Ranger™ Drug-coated balloon (DCB) offers the lowest tip-entry profile of any Superficial Femoral Artery (SFA) DCB.  When it comes to primary patency and freedom from target-lesion restenosis, you can choose Ranger with confidence, knowing  that it has demonstrated unparalleled performance across multiple randomised controlled trials (RCTs) and real-world studies

Icon representing positive result

Proven performance​
with half the drug dose1​

Icon representing trial outcomes

Highest K-M PP​
of any DCB at 3 years2-5  ​

Icon representing reduction

~8/10 TLR Free
at 4 years6-7​

Proven performance​

Such is the efficiency of the Ranger DCB drug-delivery platform, in the COMPARE RCT, it demonstrated similar primary patency* at one year as IN.PACT DCB with just half the total drug dose.1​

More confidence

Demonstrates comparable outcomes to IN.PACT with half the drug dose.1

Ranger DCB proven performance

Highest K-M Primary Patency of any DCB at 3 years​

Over three years, pivotal clinical trials show the K-M primary patency rate achieved by Ranger in the Superficial Femoral Artery (SFA) is unmatched by any other Drug-coated balloon (DCB)  – highlighting the superior long-term efficacy2-5 of this uniquely innovative product.​

More confidence

Long term Ranger demonstrated the highest K-M Primary Patency if any DCB at 3 yeras.

Ranger DCB highest KM primary patency

Low revascularisation rate at 1 and 4 years​

And what does this long-term efficacy mean for your patients? ​

It means you are giving them the best possible chance of avoiding the need for repeat intervention; 80% of Ranger DCB patients remain TLR-free at 4 years.6-7​

More successful outcomes

Ranger demonstrated a low revascularisation rate at 1 and 4 years.

Ranger DCB low revascularisation rate

Connect with us:​


1. Steiner S, Schmidt A, Zeller T, et al. COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. Eur Heart J. 2020;41(27):2541-2552. doi:10.1093/eurheartj/ehaa049.​

2. Rosenfield K, Jaff MR, White CJ, et al; LEVANT 2 Investigators. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015 Jul 9;373(2):145–53.​

3. Lyden SP, Faries PL, Niazi KAK, et al. No Mortality Signal With Stellarex Low-Dose Paclitaxel DCB: ILLUMENATE Pivotal 4-Year Outcomes. J Endovasc Ther. 2022;29(6):929–936.​

4. Schneider PA, Laird JR, Tepe G, et al; IN.PACT SFA Trial Investigators. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial. Circ Cardiovasc Interv. 2018;11(1):e005891.​

5. Brodmann M. Randomised Control Trial Data: The Pinnacle of Proof. Presented at LINC 2023, Leipzig, Germany, 6–9 June 2023.​

6. RANGER II SFA Pivotal trial 12-month results presented by Marianne Brodmann. LINC 2020.​

7. RANGER II SFA Pivotal trial 3 &4 years presented by Marianne Brodmann. LINC 2023.​

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.